Debate switches futures into positive territory after down day on Wall Street.
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
U.S. stocks moved lower ahead of Monday's first presidential debate between Donald Trump and Hillary Clinton.
The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
Conditions seem ripe for continued upward momentum in stocks, as long as the Federal Reserve or unexpected shocks don't get in the way.
With the presidential debate on the horizon, analysts are speculating how the healthcare industry could be impacted by either candidate.
Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
Hedge fund billionaire Dan Loeb owns a greater than 17% stake in the newly public developer of a drugs including those for treatment of psoriasis.
Relief over the Federal Reserve's slow-and-steady rates plans fueled another day of gains on Thursday.